Aclarion, Inc. (Nasdaq: ACON, ACONW) published a shareholder letter from CEO Brent Ness on March 19, 2026, outlining the company's strategic progress and key catalysts for 2026. The letter highlights Aclarion's efforts to expand adoption of its Nociscan platform, which uses biomarkers and augmented intelligence to help physicians identify the location of chronic low back pain.
Among the key initiatives, Aclarion is pursuing reimbursement coverage from one or more regional insurance providers in the United States. This step is seen as important toward broader payer adoption. The company also expects an initial readout from its CLARITY clinical trial in the fourth quarter of 2026. The trial is evaluating Nociscan's ability to noninvasively distinguish painful from nonpainful discs in the lumbar spine.
Brent Ness stated, 'Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business.' He emphasized increasing physician engagement, growing clinical evidence, and continued progress with payers.
Aclarion noted a strong balance sheet with cash runway into 2028, supporting continued execution. The company is a commercial-stage healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS), proprietary signal processing, biomarkers, and AI algorithms. Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs.
The full CEO Shareholder Letter is available on the company's website. For more news from Aclarion, visit their Latest News page. To find a Nociscan center, view the site map here.
